Methods of making and using dopamine receptor selective antagonists/partial agonists

A library of novel compounds that selectively bind the dopamine D3 receptor have been designed and characterized extensively.   In vivo rodent studies indicate selected lead  molecules may be useful to treat drug addiction/dependence.IC: NIDANIH Ref. No.: E-053-2016Advantages: Despite extensive efforts to develop   D3 receptor-selective compounds, it has proven difficult to identify a ligand with the desired pharmacological and pharmacokinetic profile for translation to the clinic.    The D3 receptor ligands described herein may be useful to treat a variety of diseases, including opioid use disorders and schizophrenia.Applications: Treatment of Opioid Use Disorders,  Schizophrenia, Bipolar Disorder, and of cannabis (Tetrahydrocannabinol, THC) dependenceDevelopment Status: Pre-clinical (in vivo)Updated On: Dec 20, 2017Date Published: Thursday, November 10, 2016Provider Classifications: Publications: Patent Application: 62/307,600Licensing Contacts: Lead Inventor: Inventor IC: NIDANIDAInventor Lab URL: https://irp.drugabuse.gov/Newman.phpInv Is lead: LPM Phone: [phone]LPM Email: [e-mail] Classification: TherapeuticsDTDT Description: TherapeuticsPat Filing Date: 2016-03-14T00:00:00Publication Link: https://www.ncbi.nlm.nih.gov/pubmed/27508895Publication Caption: PMID: 27508895Publication Title: Newman A. et al.Collaboration Sought: Yes...

Source: NIH OTT Licensing Opportunities - November 10, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research